M 1145

Product Name:M 1145

CAS No:1172089-00-7

Purity:95%

Molar Mass:2774.26

Chemical Formula:C128H205N37O32

Storage:Store at -20 degrees Celsius

Sequence:RGRGNWTLNSAGYLLGPVLPPPALALA

Target:galanin receptor 2

Application:

M 1145 is a selective antagonist for the galanin receptor 2 (GalR2). This receptor is involved in a range of physiological processes, including modulation of neurotransmission, pain, and appetite. By blocking GalR2, M 1145 is used to study the receptor's specific roles in these processes and to investigate its potential as a therapeutic target for conditions such as mood disorders, chronic pain, and metabolic disorders. The peptide's specificity for GalR2 helps researchers understand its function and explore new treatment avenues for related diseases.

Current Research:

M 1145, a potent and selective agonist of the galanin receptor subtype 2 (GAL2), has garnered significant interest in pharmaceutical and bioscience research due to its specificity and potential therapeutic applications. The compound exhibits high affinity for GAL2, with a Ki value of 6.55 nM, and demonstrates substantially lower affinity for GAL1 and GAL3, with Ki values of 587 nM and 497 nM, respectively. This selectivity profile underscores its utility in modulating GAL2-mediated physiological processes. Recent studies have explored the biological activity of M 1145, revealing its additive effect on galanin-induced signal transduction. Concentrations of M 1145 at 0.1 μM and higher have been shown to achieve maximum transduction, indicating its efficacy in activating GAL2 pathways. This property positions M 1145 as a valuable tool for investigating the role of GAL2 in various biological systems. The therapeutic potential of M 1145 extends to several domains, including neurobiology and metabolic regulation. Activation of GAL2 has been implicated in neuroprotective effects, modulation of mood disorders, and regulation of feeding behavior. Therefore, M 1145 serves as a critical agent in elucidating GAL2 functions and assessing its viability as a therapeutic target. Despite its promise, the commercial availability of M 1145 has been limited. Suppliers such as Tocris Bioscience have discontinued the product for commercial reasons, which may impact ongoing and future research endeavors. This discontinuation highlights the necessity for alternative sources or the development of new GAL2-selective agonists to continue advancing research in this area. In conclusion, M 1145 remains a compound of considerable interest within the pharmaceutical and bioscience communities. Its high selectivity for GAL2 and the subsequent biological effects make it a pivotal molecule for studying galanin receptor-mediated mechanisms. Ongoing research is essential to fully understand its potential applications and to develop strategies for its sustained availability for scientific investigation.

Reference:

Runesson, J., Saar, I., Lundström, L., Järv, J., & Langel, Ü. (2009). A novel GalR2-specific peptide agonist. Neuropeptides, 43(3), 187-192.